Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS
Cancer,
Kadia TM et al. – RAS mutations in acute myeloid leukemia (AML) may delineate a subset of patients who benefit from AraC–based therapy and who may be amenable to treatment with inhibitors of RAS and PI3K signaling pathways.



